Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

NCT05687123 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05687123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05687123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
August 14, 2024
Completion date
December 14, 2026
Enrollment
24 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic neuroendocrine tumor, pancreatic neoplasm, stage iii pancreatic neuroendocrine tumor ajcc v8, stage iv pancreatic neuroendocrine tumor ajcc v8, unresectable pancreatic neuroendocrine tumor